Review
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Immunol. Nov 27, 2013; 3(3): 31-43
Published online Nov 27, 2013. doi: 10.5411/wji.v3.i3.31
Probiotics in inflammatory bowel disease: Pathophysiological background and clinical applications
Cristiano Pagnini, Gianfranco Delle Fave, Giorgos Bamias
Cristiano Pagnini, Gianfranco Delle Fave, Faculty of Medicine and Psychology, S.Andrea Hospital, Sapienza University, Rome 00189, Italy
Giorgos Bamias, Academic Department of Gastroenterology, Laikon Hospital, Ethnikon and Kapodistriakon University, Athens 11527, Greece
Author contributions: Pagnini C and Bamias G designed the review and wrote the paper; Delle Fave G contributed to the editing of the paper.
Correspondence to: Giorgos Bamias, MD, Consultant in Gastroenterology, Academic Department of Gastroenterology, Laikon Hospital, Ethnikon and Kapodistriakon University, 17 Agiou Thoma Street, Athens 11527, Greece. gbamias@gmail.com
Telephone: +30-210-7456504 Fax: +30-210-7791839
Received: June 30, 2013
Revised: August 6, 2013
Accepted: August 12, 2013
Published online: November 27, 2013
Abstract

Ulcerative colitis and Crohn’s disease, collectively termed the inflammatory bowel diseases (IBD), are chronic inflammatory disorders of the gastrointestinal tract. A “dysbiotic” relationship between the commensal gut flora and the intestinal mucosa-associated immune system has been at the core of the pathogenesis of these conditions. Probiotics are “good bacteria” with the ability to benefit the health of the host and their therapeutic application has been studied in IBD. The theoretical basis for such utilization relies upon the ability of probiotic microorganisms to interfere with the dysregulated homeostasis that takes place in IBD and restore the immune-bacterial interaction at the intestinal mucosa. Proposed mechanisms of action include the reconstitution of altered flora composition, enhancement of the integrity of the epithelial barrier, promotion of tolerogenic action by dendritic cells, strengthening of the defensive mechanisms of the innate immunity, and the suppression of pro-inflammatory adaptive immune responses. Despite this abundance of supporting experimental evidence, clinical application of probiotics in IBD has been disappointing. Possible explanations for such discrepancy include the great diversity of microorganisms that fall under the definition of probiotics, the lack of standardization of dosages and administration schemes, the heterogeneity between clinical trials, and the inclusion in the treatment arms of patients with a large variety of clinical phenotypes. Addressing these important issues will be critical for the optimal usage of probiotic-based therapies for patients with IBD.

Keywords: Probiotics, Commensal flora, Mucosa-associated immune system, Inflammatory bowel disease, Clinical trials, Pouchitis, Ulcerative colitis, Crohn’s disease

Core tip: Inflammatory bowel diseases are chronic debilitating diseases of the gastrointestinal tract. Current therapies are not effective in a great proportion of patients and are associated with serious adverse effects. The use of probiotics has been tried as an alternative and safe treatment. Herein, we review the pathophysiological basis for such an application and summarize the data from the major clinical trials.